Genexine, Merck to study HPV vaccine combo

Genexine Inc. (KOSDAQ:095700) and Merck & Co. Inc. (NYSE:MRK) partnered to conduct a Phase Ib/IIa trial evaluating Genexine's GX-188E in combination with Merck's Keytruda pembrolizumab to treat HPV-induced cancers. Genexine will conduct the study, which is slated to begin in 1H17 and enroll up to 40 patients. The companies may expand the partnership to include Phase III studies in the indication.

Genexine received funding from the Korean government to develop GX-188E, a plasmid DNA therapeutic vaccine (see BioCentury, March 21). ...